Yescarta (Axicabtagene) Denied by Insurance? How to Appeal

Yescarta (Axicabtagene) Denied by Insurance? How to Appeal

Yescarta is a FDA-approved CAR-T cell therapy that has transformed outcomes for patients with relapsed or refractory large B-cell lymphoma. It is one of the most clinically significant cancer treatments developed in the past decade. It is also routinely denied by insurers — despite explicit FDA approval, NCCN Category 1 status, and a list price of $373,000 to $450,000 that makes it a prime target for cost-based denials dressed up as clinical decisions.

If Yescarta was denied, you can appeal. Patients who appeal with proper documentation — FDA approval plus NCCN Category 1 guidelines — win at External Independent Review: Complete Guide" class="auto-link">external review at a high rate.

What Yescarta Is and What It Treats

Yescarta (axicabtagene ciloleucel) is a CAR-T (chimeric antigen receptor T-cell) therapy developed by Kite Pharma and marketed by Gilead Sciences. It works by taking a patient's own T-cells, genetically engineering them to express a chimeric antigen receptor targeting CD19, and reinfusing them to attack and destroy CD19-positive cancer cells.

FDA approval history:

• October 2017: Initial FDA approval for relapsed/refractory large B-cell lymphoma (DLBCL, HGBCL, PMBCL, transformed follicular lymphoma) in adults after two or more prior lines of systemic therapy
• April 2022: FDA expanded approval to include relapsed/refractory follicular lymphoma after two or more prior lines of systemic therapy

This approval history matters enormously for appeals. Yescarta has been FDA-approved since 2017 — nearly a decade. An insurer calling it "experimental" in 2026 is making a factually false statement that external reviewers will reject.

Cost: approximately $373,000 to $450,000 per infusion, not including hospital and supportive care costs.

Why Yescarta Claims Are Denied

"Experimental or investigational." This is the most common — and most legally vulnerable — denial reason. FDA approval in the specific indication is definitive proof that a treatment is not experimental. The FDA approval process requires demonstration of safety and efficacy to a rigorous evidentiary standard. An insurer cannot simultaneously acknowledge FDA approval and classify the treatment as experimental for the approved indication.

"Not medically necessary." For relapsed/refractory DLBCL after two prior lines of therapy, Yescarta is NCCN Category 1 — the highest evidence category. Medical necessity is established by definition when a treatment has NCCN Category 1 evidence for the patient's specific indication and line of therapy.

"Out-of-network infusion center." Yescarta must be administered at FDA-authorized treatment centers — hospitals with specific training and certification for CAR-T administration, cytokine release syndrome management, and REMS program compliance. Many of these centers are academic medical centers that may be out of network for some commercial plans. This triggers network adequacy protections, not a coverage exclusion.

PA not obtained timely. Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization for Yescarta must be obtained before leukapheresis (the cell collection process) begins. If PA is not in place before manufacturing begins, retroactive denial risk is high.

FDA Approval Defeats the "Experimental" Argument

Under the ACA's prohibition on lifetime and annual limits, and under most state insurance codes, "experimental or investigational" exclusions cannot apply to treatments that have received FDA approval for the patient's specific indication.

The legal structure is straightforward:

1. The insurer's policy excludes "experimental or investigational" treatments
2. The insurer claims Yescarta is experimental
3. Yescarta has FDA approval specifically for relapsed/refractory DLBCL (or follicular lymphoma)
4. FDA approval in the specific indication is the legal and regulatory standard for "not experimental"
5. Therefore the exclusion does not apply

External reviewers — IROs) Explained" class="auto-link">Independent Review Organizations — apply this logic consistently. Cite the FDA approval letter date, the specific indication approved, and the ACA's prohibition on experimental exclusions for FDA-approved treatments.

NCCN Category 1: Medical Necessity Established

The National Comprehensive Cancer Network B-Cell Lymphomas guidelines designate Yescarta (axicabtagene ciloleucel) as a Category 1 recommendation for:

• Relapsed/refractory large B-cell lymphoma after two prior lines of therapy
• Relapsed/refractory follicular lymphoma after two prior lines of therapy

NCCN Category 1 means: "Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate."

Print the relevant NCCN B-Cell Lymphomas or Follicular Lymphoma guideline pages and include them in your appeal. Most commercial insurance plans and Medicare explicitly reference NCCN guidelines in their coverage policies. When NCCN Category 1 evidence supports a treatment, a medical necessity denial cannot be sustained.

Single Case Agreement: When There Is No In-Network CAR-T Center

If the denial is based on the treating center being out of network, invoke your insurer's network adequacy obligations.

Yescarta can only be administered at FDA-authorized CAR-T treatment centers with REMS certification. Your insurer is legally required to maintain an adequate network for covered services. If no in-network provider offers Yescarta administration within a reasonable distance, the insurer must cover the out-of-network provider at in-network rates or negotiate a single case agreement.

To pursue a single case agreement:

1. Request one in writing, addressed to the insurer's network management or case management department
2. Have your oncologist document why this specific FDA-authorized center is required for Yescarta administration
3. Include documentation of the center's CAR-T authorization and REMS certification
4. Cite your state's network adequacy regulations and the ACA's access to care provisions
5. Copy your state insurance commissioner on the request if the insurer does not respond within 5 business days

External Review: The Critical Final Step

If your internal appeal is denied, file for external review immediately. Do not delay. Oncology cases — especially CAR-T cases — are often expedited.

IROs consistently overturn Yescarta denials when patients present:

• FDA approval documentation for the specific indication
• NCCN Category 1 guideline support
• Oncologist letter documenting the specific diagnosis and prior therapy lines

There is no clinically defensible basis for denying an FDA-approved, NCCN Category 1 treatment to a patient who meets the approved indication. External reviewers reach this conclusion regularly.

Documentation Checklist

• Denial letter with specific denial reason and clinical criteria cited
• FDA approval label for Yescarta (available at FDA.gov — include the specific indication language)
• FDA approval date documentation (October 2017 initial approval; April 2022 FL expansion)
• NCCN B-Cell Lymphomas or Follicular Lymphoma guideline pages with Category 1 designation highlighted
• Oncologist letter documenting: specific diagnosis, staging, prior chemotherapy lines and outcomes
• Pathology report confirming specific indication (e.g., DLBCL, HGBCL, FL) with CD19 status
• Records of prior chemotherapy regimens (names, dates, response/failure documentation)
• Treating center's CAR-T authorization and REMS certification documentation
• Single case agreement request (if out-of-network denial)
• Network adequacy complaint (if applicable)

Fight Back With ClaimBack

ClaimBack analyzes your Yescarta denial and generates an oncologist-ready appeal package built on FDA approval documentation and NCCN Category 1 evidence.

Start your free appeal analysis at ClaimBack

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• What Is Medical Necessity?
• Internal vs. External Insurance Appeal: Which Should You File?
• Common Reasons Insurance Claims Are Denied